Norges Bank
HRTX icon

Norges Bank’s Heron Therapeutics HRTX Stock Holding History

Norges Bank’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-279,000
Closed -$421K – 2055
2023
Q1 		$421K Hold
279,000
– – ﹤0.01% 2057
2022
Q4 		$698K Buy
+279,000
New +$899K ﹤0.01% 2080
2022
Q3 		– Sell
-887,122
Closed -$2.48M – 2106
2022
Q2 		$2.48M Buy
887,122
+63,800
+8% +$256K ﹤0.01% 1876
2022
Q1 		$4.71M Buy
823,322
+14,362
+2% +$105K ﹤0.01% 1882
2021
Q4 		$7.39M Buy
808,960
+95
+0% +$970 ﹤0.01% 1836
2021
Q3 		$8.65M Buy
808,865
+209,000
+35% +$2.54M ﹤0.01% 1808
2021
Q2 		$9.31M Buy
599,865
+746
+0.1% +$11.9K ﹤0.01% 1802
2021
Q1 		$9.71M Sell
599,119
-567,486
-49% -$10.1M ﹤0.01% 1791
2020
Q4 		$24.7M Sell
1,166,605
-213,666
-15% -$3.71M 0.01% 1439
2020
Q3 		$20.5M Sell
1,380,271
-104,144
-7% -$1.62M 0.01% 1408
2020
Q2 		$21.8M Buy
1,484,415
+354,417
+31% +$5.82M 0.01% 1377
2020
Q1 		$13.3M Buy
1,129,998
+134,918
+14% +$2.54M ﹤0.01% 1488
2019
Q4 		$23.4M Buy
995,080
+193,289
+24% +$4.28M 0.01% 1443
2019
Q3 		$14.8M Buy
801,791
+76,268
+11% +$1.4M ﹤0.01% 1628
2019
Q2 		$13.5M Buy
725,523
+78,383
+12% +$1.57M ﹤0.01% 1695
2019
Q1 		$15.8M Buy
647,140
+119,789
+23% +$3.14M 0.01% 1632
2018
Q4 		$13.7M Buy
527,351
+70,912
+16% +$1.95M 0.01% 1603
2018
Q3 		$14.4M Buy
456,439
+406,439
+813% +$15.1M ﹤0.01% 1687
2018
Q2 		$1.94M Buy
+50,000
New +$1.59M ﹤0.01% 2027
2017
Q4 		– Sell
-20,000
Closed -$323K – 2126
2017
Q3 		$323K Hold
20,000
– – ﹤0.01% 2109
2017
Q2 		$277K Hold
20,000
– – ﹤0.01% 2106
2017
Q1 		$300K Buy
+20,000
New +$277K ﹤0.01% 2125

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Norges Bank's HRTX Position: Q2 2023 in Review

Norges Bank sold out of Heron Therapeutics (HRTX) in Q2 2023, closing a stake of 279,000 shares — an estimated $421K sold.

Norges Bank first reported a position in HRTX in Q1 2017 and held it in 22 quarters. The position peaked at $24.7M in Q4 2020. 149 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

  • Norges Bank reported no remaining Heron Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Norges Bank sold 279,000 Heron Therapeutics shares in Q2 2023, an estimated $421K.
  • Norges Bank first reported a position in Heron Therapeutics in Q1 2017 and held it in 22 quarters.
  • Norges Bank's Heron Therapeutics position peaked at $24.7M in Q4 2020.
  • 149 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on Norges Bank's 13F filing for Q2 2023, filed 14 Aug 2023.